Cargando…

Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival

Recent studies suggest that inflammation response biomarkers are prognostic indicators of solid tumor outcomes. Here, we quantify the prognostic value of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in glioblastomas (GBMs), taki...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Peng-Fei, Song, Hong-Wang, Cai, Hong-Qing, Kong, Ling-Wei, Yao, Kun, Jiang, Tao, Li, Shou-Wei, Yan, Chang-Xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564834/ https://www.ncbi.nlm.nih.gov/pubmed/28223536 http://dx.doi.org/10.18632/oncotarget.15235

Ejemplares similares

IDH-1(R132H) mutation status in diffuse glioma patients: implications for classification
por: Wang, Peng-fei, et al.
Publicado: (2016)

Preoperative Changes in Hematological Markers and Predictors of Glioma Grade and Survival
por: Wang, Peng-Fei, et al.
Publicado: (2018)

Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1(R132H) mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss
por: Cai, Hong-Qing, et al.
Publicado: (2018)

Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
por: Chen, Jun-Rui, et al.
Publicado: (2016)

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status()
por: Myung, Jae Kyung, et al.
Publicado: (2014)

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
por: Yang, Pei, et al.
Publicado: (2015)

The NADP(+)-dependent IDH1 mutation and its relevance for glioblastoma patient survival
por: Van Noorden, Cornelis JF
Publicado: (2014)

IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients
por: Amelot, Aymeric, et al.
Publicado: (2015)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
por: Haider, Ali S., et al.
Publicado: (2023)

Higher Plasma Fibrinogen Levels are Associated with Malignant Phenotype and Worse Survival in Patients with Glioblastomas
por: Wang, Peng-Fei, et al.
Publicado: (2018)

Association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas
por: Liouta, Evangelia, et al.
Publicado: (2022)

PREOPERATIVE DETERMINATION OF IDH STATUS AND GRADE IN GLIOMAS USING MRS
por: Nguyen, Thanh Binh
Publicado: (2023)

Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status
por: Tabei, Yusuke, et al.
Publicado: (2020)

Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma
por: Liu, Elisa K, et al.
Publicado: (2022)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
por: Krell, Daniel, et al.
Publicado: (2011)

Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022)

Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
por: Wang, Zheng, et al.
Publicado: (2013)

MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status
por: Li, Guanzhang, et al.
Publicado: (2018)

IDH1/IDH2 but Not TP53 Mutations Predict Prognosis in Bulgarian Glioblastoma Patients
por: Stancheva, Gergana, et al.
Publicado: (2014)

IDH1 mutations in a Brazilian series of Glioblastoma
por: Uno, Miyuki, et al.
Publicado: (2011)

Preoperative neurocognitive function as an independent survival prognostic marker in primary glioblastoma
por: Liouta, Evangelia, et al.
Publicado: (2023)

The prognostic IDH1(R132) mutation is associated with reduced NADP(+)-dependent IDH activity in glioblastoma
por: Bleeker, Fonnet E., et al.
Publicado: (2010)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Metabolic Rewiring in Glioblastoma Cancer: EGFR, IDH and Beyond
por: El Khayari, Abdellatif, et al.
Publicado: (2022)

Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
por: Chai, Ruichao, et al.
Publicado: (2021)

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
por: Radke, Josefine, et al.
Publicado: (2019)

EGFR Amplification and IDH Mutations in Glioblastoma Patients of the Northeast of Morocco
por: Senhaji, Nadia, et al.
Publicado: (2017)

The immune regulation of BCL3 in glioblastoma with mutated IDH1
por: Fan, Shibing, et al.
Publicado: (2022)

Implications of Concurrent IDH1 and IDH2 Mutations on Survival in Glioma—A Case Report and Systematic Review
por: Yuile, Alexander, et al.
Publicado: (2022)

Prediction of BRAF mutation status in glioblastoma multiforme by preoperative ring enhancement appearances on MRI
por: Cai, Xiaomin, et al.
Publicado: (2022)

Peripheral Inflammatory Blood Markers in Diagnosis of Glioma and IDH Status
por: Sharma, Gaurav, et al.
Publicado: (2021)

Phosphorous Magnetic Resonance Spectroscopy and Molecular Markers in IDH1 Wild Type Glioblastoma
por: Galijašević, Malik, et al.
Publicado: (2021)

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
por: Wang, Hao-Yuan, et al.
Publicado: (2016)

Prognostic analysis and nomogram construction for older patients with IDH-wild-type glioblastoma
por: Cao, Wenjun, et al.
Publicado: (2023)

Sanbo Scoring System, Based on Age and Pre-treatment Hematological Markers, is a Non-invasive and Independent Prognostic Predictor for Patients with Primary Glioblastomas: A Retrospective Multicenter Study
por: Wang, Peng-fei, et al.
Publicado: (2019)

Molecular classification of IDH-mutant glioblastomas based on gene expression profiles
por: Wu, Fan, et al.
Publicado: (2019)

Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses
por: Liu, Yu-Qing, et al.
Publicado: (2019)

Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival
por: Chaurasia, Ajay, et al.
Publicado: (2016)

Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma
por: Bagley, Stephen J, et al.
Publicado: (2021)

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
por: Le, Nguyen Quoc Khanh, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bhq5c6n8lr6ht4ot3omgq4tttn